ArticleJournal of biosciences2003
Expression of the neurotrophin receptors Trk A and Trk B in adult human astrocytoma and glioblastoma.
Article in Journal of biosciences, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 64 citations in OpenAlex.
- Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene.Cancer gene therapy · 2024Article
- Neurons as stromal drivers of nervous system cancer formation and progression.Developmental cell · 2023Review
- Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China.Thoracic cancer · 2022Article
- Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme.International journal of molecular sciences · 2021Review
- Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients.Current oncology (Toronto, Ont.) · 2021Article
- Old Stars and New Players in the Brain Tumor Microenvironment.Frontiers in cellular neuroscience · 2021Review
- NTRK Fusions, from the Diagnostic Algorithm to Innovative Treatment in the Era of Precision Medicine.International journal of molecular sciences · 2020Review
- NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma.Frontiers in oncology · 2020Review
- Mouse Nerve Growth Factor Facilitates the Growth of Interspinal Schwannoma Cells by Activating NGF Receptors.Journal of Korean Neurosurgical Society · 2019Article
- Article
- Article
- Targetome Analysis Revealed Involvement of MiR-126 in Neurotrophin Signaling Pathway: A Possible Role in Prevention of Glioma Development.Cell journal · 2018Article
- Reciprocal Signaling between Glioblastoma Stem Cells and Differentiated Tumor Cells Promotes Malignant Progression.Cell stem cell · 2018Article
- Neuronal activity in the glioma microenvironment.Current opinion in neurobiology · 2017Review
- Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.The American journal of surgical pathology · 2017Article
- Targeting tyrosine receptor kinase B in gliomas.Neuro-oncology · 2017Article
- Nerve growth factor: role in growth, differentiation and controlling cancer cell development.Journal of experimental & clinical cancer research : CR · 2016Review
- Comparative transcriptomics reveals similarities and differences between astrocytoma grades.BMC cancer · 2015Article
- Neurotrophin signaling via TrkB and TrkC receptors promotes the growth of brain tumor-initiating cells.The Journal of biological chemistry · 2015Article
- Deregulated proliferation and differentiation in brain tumors.Cell and tissue research · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurotrophins and their receptors of the Trk family play a critical role in proliferation, differentiation and survival of the developing neurons. There are reports on their expression in neoplasms too, namely, the primitive neuroectodermal tumours of childhood, and in adult astrocytic gliomas. The involvement of Trk receptors in tumour pathogenesis, if any, is not known. With this end in view, the present study has examined 10 tumour biopsy samples (identified as astrocytoma, pilocytic astrocytoma and glioblastoma) and peritumoral brain tissue of adult patients, for the presence of Trk A and Trk B receptors, by immunohistochemistry. The nature of the tumour samples was also confirmed by their immunoreactivity (IR) to glial fibrillary acidic protein. In the peritumoral brain tissue, only neurons showed IR for Trk A and Trk B. On the contrary, in the tumour sections, the IR to both receptors was localized in the vast majority of glia and capillary endothelium. There was an obvious pattern of IR in these gliomas: high levels of IR were present in the low-grade (type I and II) astrocytoma; whereas in the advanced malignant forms (WHO grade IV giant cell glioblastoma and glioblastoma multiforme) the IR was very weak. These findings suggest that Trk A and Trk B are involved in tumour pathogenesis, especially in the early stage, and may respond to signals that elicit glial proliferation, and thus contribute to progression towards malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.